rhythm Cellusync

Researchers investigated the effects of daily Uthever® NMN supplementation in healthy middle aged and older adults, comparing 300 mg NMN with a placebo over 60 days.

What did they find?

• NAD+ levels: Blood NAD+/NADH levels increased by 11.3% at day 30, while the placebo group showed no change.
• Sustained increase: By day 60, NAD+/NADH levels had increased by 38% from baseline, compared with 14.3% in the placebo group.
• Overall wellbeing: SF-36 health survey scores improved by 6.5% in the NMN group, compared with 3.4% in the placebo group.
• Safety observations: Laboratory tests showed no clinically meaningful changes, and no obvious side effects were reported.

These findings suggest that daily NMN supplementation may increase blood NAD+/NADH levels and support aspects of overall wellbeing.

Study details: Randomised, multicentre, double blind, placebo controlled trial · 66 healthy adults aged 40 and above · 300 mg Uthever® NMN daily · 60 days · Blood NAD+/NADH, SF-36 health survey, safety laboratory and organ function tests.

Researchers investigated the effects of three daily NMN doses in healthy middle aged adults, comparing 300 mg, 600 mg and 900 mg NMN with a placebo over 60 days.

What did they find?

• NAD+ levels: Blood NAD+ levels increased in a dose dependent manner, with the highest levels reported in the 600 mg and 900 mg groups.
• Walking performance: Participants receiving NMN showed significantly greater improvements in six minute walk distance than the placebo group at all three doses.
• Duration of effects: Improvements in blood NAD+ levels and walking performance were reported at both day 30 and day 60.
• Safety and tolerability: NMN was reported to be safe and well tolerated at doses up to 900 mg daily during the study.

These findings suggest that NMN supplementation may support NAD+ availability and aspects of physical performance.

Study details: Randomised, multicentre, double blind, placebo controlled, dose response trial · 80 healthy adults aged 40 to 65 · 300 mg, 600 mg or 900 mg NMN daily · 60 days · Blood NAD+, six minute walk test, SF-36, safety and tolerability.

Researchers measured NAD+ levels in human tissue samples from individuals across a broad age range to investigate the relationship between NAD+ availability, ageing and markers of cellular stress.

What did they find?

• NAD+ levels: NAD+ levels showed a strong negative correlation with age in both men and women.
• Cellular stress: As NAD+ levels declined, markers of cellular stress and DNA damage increased.
• DNA repair: The findings suggested a relationship between declining NAD+ and changes in pathways involved in DNA repair.
• Ageing pathways: The authors proposed that declining NAD+ may contribute to ageing related changes in cellular energy production and genomic signalling.

These findings suggest that NAD+ levels are associated with age related changes in human tissues. However, this study demonstrates an association and does not establish that declining NAD+ directly causes ageing or that NMN supplementation reverses these changes.

Study details: Human tissue study · Men and women aged 0 to 77 years · Assessment of NAD+ levels, oxidative stress markers, PARP and SIRT1 activity.

Researchers at Washington University investigated the effects of long term NMN supplementation in mice during normal ageing. NMN was administered through drinking water for 12 months to examine its effects on NAD+ availability, energy metabolism, physical activity and age related changes in organ function.

What did they find?

• NAD+ availability: Oral NMN was rapidly utilised to support NAD+ production in tissues.
• Energy metabolism: NMN enhanced energy metabolism during normal ageing.
• Physical activity: Treated mice showed improvements in physical activity.
• Mitochondrial function: NMN supported mitochondrial metabolism in skeletal muscle.
• Eye function: Improvements in eye function were reported.
• Age related gene expression: NMN helped prevent age related changes in gene expression across key organs.
• Long term safety: No obvious toxicity was observed during the 12 month study.

These findings suggest that NMN may support NAD+ availability and several aspects of physiological function during ageing.

Study details: Preclinical animal study · Mice undergoing normal ageing · NMN administered in drinking water for 12 months · Assessment of tissue NAD+, energy metabolism, physical activity, eye function, mitochondrial function, gene expression and long term safety.

This study investigated the relationship between NAD+ metabolism and the circadian clock using cell and mouse models. Researchers examined how clock genes regulate NAMPT, an enzyme involved in NAD+ recycling, and how NAD+ feeds back into the clock's regulatory mechanisms.

What did they find?

• Daily NAD+ rhythm: Intracellular NAD+ levels rose and fell in a 24 hour cycle.
• Clock gene regulation: CLOCK and BMAL1 regulated NAMPT expression, influencing NAD+ production.
• NAD+ recycling: NAMPT played a key role in maintaining NAD+ availability through its salvage pathway.
• Feedback mechanism: NAD+ dependent SIRT1 activity fed back into the circadian clock, linking NAD+ metabolism with clock regulation.

These findings demonstrate a mechanistic connection between NAD+ metabolism and the circadian clock in preclinical models. They highlight the importance of biological timing in cellular processes.

Study details: Preclinical mechanism study · Cell and mouse models · Circadian NAD+ oscillation, NAMPT expression and the CLOCK–SIRT1 feedback loop.

In May 2026, the European Food Safety Authority (EFSA) published a positive scientific opinion on the safety of β-NMN from EffePharm, the ingredient used in Uthever®. The assessment evaluated its proposed use as a novel food in food supplements.

What did they find?

• Daily intake: EFSA concluded that 300 mg of β-NMN per day is safe for the general adult population under the proposed conditions of use.
• Safety assessment: The opinion followed a scientific assessment by EFSA's Panel on Nutrition, Novel Foods and Food Allergens (NDA).
• Regulatory recognition: According to the supplied source, Uthever® also holds an FDA New Dietary Ingredient notification (NDI 1267).

This positive opinion provides regulatory safety support for β-NMN at the assessed intake and under the specified conditions of use.

Study details: Regulatory scientific opinion · EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) · Safety of β-NMN as a novel food in food supplements.